Baiya Phytopharm Partners with KAICO through MoU on Protein Expression Services

News

Fukuoka, Japan, October 8, 2025 – Baiya Phytopharm (“Baiya”) is pleased to announce it has signed a Memorandum of Understanding (MoU) with KAICO Ltd. (“KAICO”) to collaboratively explore and develop complementary strategies in the field of recombinant protein expression services. Under this MoU, both companies will work together to expand service offerings, deepen technical cooperation, and accelerate the translation of novel biologics. 

Under the MoU, Baiya and KAICO have agreed to focus on: 
　1. Referral of Projects on the Contract Protein Expression Service 
　2. Mutual Complementation of Reagent Lineups 

Through this MoU, Baiya and KAICO aim to: 

Leverage complementary strengths—KAICO’s silkworm-baculovirus expression system and Baiya’s plant-based system—to offer broader choices and enhanced capacity. 

Expand each party’s geographic reach and customer base via reagent cross-licensing and project referrals. 

About KAICO 

KAICO, founded as a startup from Kyushu University, advances a proprietary silkworm–baculovirus expression system, using silkworm pupae as bioreactors for recombinant protein production. The company offers custom protein expression services, research reagents, and is actively developing vaccine candidates for both veterinary and human health applications. 

Leveraging this agreement as a catalyst, KAICO remains committed to expanding strategic partnerships across alternative protein expression systems, human and animal healthcare and related fields, accelerating its journey toward impactful innovation. 

About Baiya Phytopharm 

Baiya Phytopharm, established in 2018 as a spin-off from Chulalongkorn University in Thailand, is a clinical-stage biopharmaceutical company that leverages its proprietary BaiyaPharming™ plant-based platform to develop therapeutics, vaccines, and recombinant proteins. 

Baiya’s platform has demonstrated speed and flexibility in producing biologic molecules and has advanced multiple pipeline candidates including multifunctional antibody derivatives in immuno-oncology and infectious disease fields.  

Baiya Phytopharm Partners with KAICO through MoU on Protein Expression Services

Fukuoka, Japan, October 8, 2025 – Baiya Phytopharm (“Baiya”) is pleased to announce it has signed a Memorandum of Understanding (MoU) with KAICO Ltd. (“KAICO”) to collaboratively explore and develop complementary strategies in the field of recombinant protein expression services. Under this MoU, both companies will work together to expand service offerings, deepen technical cooperation, and accelerate the translation of novel biologics. 

Under the MoU, Baiya and KAICO have agreed to focus on: 
　1. Referral of Projects on the Contract Protein Expression Service 
　2. Mutual Complementation of Reagent Lineups 

Through this MoU, Baiya and KAICO aim to: 

Leverage complementary strengths—KAICO’s silkworm-baculovirus expression system and Baiya’s plant-based system—to offer broader choices and enhanced capacity. 

Expand each party’s geographic reach and customer base via reagent cross-licensing and project referrals. 

About KAICO 

KAICO, founded as a startup from Kyushu University, advances a proprietary silkworm–baculovirus expression system, using silkworm pupae as bioreactors for recombinant protein production. The company offers custom protein expression services, research reagents, and is actively developing vaccine candidates for both veterinary and human health applications. 

Leveraging this agreement as a catalyst, KAICO remains committed to expanding strategic partnerships across alternative protein expression systems, human and animal healthcare and related fields, accelerating its journey toward impactful innovation. 

About Baiya Phytopharm 

Baiya Phytopharm, established in 2018 as a spin-off from Chulalongkorn University in Thailand, is a clinical-stage biopharmaceutical company that leverages its proprietary BaiyaPharming™ plant-based platform to develop therapeutics, vaccines, and recombinant proteins. 

Baiya’s platform has demonstrated speed and flexibility in producing biologic molecules and has advanced multiple pipeline candidates including multifunctional antibody derivatives in immuno-oncology and infectious disease fields.